Report
Peter Thilo Hasler

Attraktive Produkte in klinischer Entwicklung

Im abgelaufenen Geschäftsjahr (30.09.) erzielte Sanochemia Erlöse von EUR 41,4 Mio. (Sphene Capital: EUR 39,3 Mio., +5,2% YoY). Dynamisch verlief die Entwicklung im vierten Quartal, in dem die Erlöse auf EUR 14,1 Mio. und damit um 11,9% anstiegen. Hauptverantwortlich dafür waren insbesondere radiologische Produkte aus dem Segment Humanpharmazeutika, das sowohl von höheren Umsätzen in bestehenden und Produkteinführungen in neuen Märkten als auch von neuen Produkten profitierte. Ebenfalls deutlich über dem Vorjahreswert lag das EBITDA, das sich auf EUR 4,1 Mio. von EUR 3,6 Mio. (+13,2% YoY) verbesserte und damit deutlich über unseren Prognosen (EUR 2,4 Mio.) lag. Dabei konnte im (ertragsseitig typischerweise schwachen) vierten Quartal mit einem EBITDA in Höhe von EUR 1,7 Mio. ein nahezu gleich hohes EBITDA wie in den ersten drei Quartalen zusammengenommen erwirtschaftet werden. Auch trotz Berücksichtigung höherer Refinanzierungskosten aus der Tilgung der Mittelstandsanleihe hat sich das Ergebnis vor Steuern auf EUR -0,2 Mio. gegenüber dem Vorjahreswert von knapp EUR -0,5 Mio. deutlich verbessert. Wir ermitteln ein Kursziel von EUR 2,90 je Aktie (bislang EUR 2,80) und bestätigen unser Buy-Rating für die Aktien der Sanochemia Pharmazeutika AG.

Underlying
Sanochemia Pharmazeutika AG

Sanochemia Pharmazeutika is engaged in the development and manufacture of novel drugs diagnostics for use in the treatment of neurodegeneration, pain and oncology. Co. operates through three main business divisions. The Research and Development division is responsible for Co.focuses on projects such as PVP hypericine, for the photodynamic diagnosis and therapy of bladder cancer, and Secrelux, a pancreas function diagnostic. The Production division is engaged in the synthesis of active pharmaceutical substances (APIs), drug formulation and pharmaceutical production. Co.'s Human Pharmaceuticals division is engaged in the sale of APIs, drug formulation and pharmaceutical production..

Provider
Sphene Capital GmbH
Sphene Capital GmbH

Founded in 2010, Sphene Capital is a German based pure-play research house offering state-of-the-art research and evaluation services to European small- and mid-caps by avoiding typical conflict of interests of traditional investment banks.

As a general rule, analysts of Sphene Capital strive to understand companies better than any other analyst or investor before publishing their initiation reports. Therefore, the comprehensive initiation research reports comprise of 50-80 pages, including an extensive analysis of the value chain of the IPO candidate, its unique selling proposition, an elaborate analysis of suppliers and clients, a thorough SWOT analysis, a commercial due diligence (i. e. market and competitive analysis), an integrated financial forecast model and a profound company valuation (both DCF methodology and peer group multiples). Before publication, each of Sphene Capital’s research report will be double-checked by a fellow research colleague (“Four-eyes-principle”), ensuring highest quality and avoiding careless mistakes.

After initiation of research coverage, Sphene Capital publishes regular updates of 12-30 pages following relevant news flow from the issuer or major peers, f. ex. after acquisitions or after publication of quarterly results.

Due to Sphene Capital’s extensive experience in equity and bond research, the team has established longstanding contacts to all relevant market players, i. e. institutional investors, family offices and high net-worth individuals as well as journalists. To each of these groups, Sphene Capital’s research analysts have regular contacts during analyst and management roadshows or via daily phone calls. Finally, analysts publish articles in selected stock markets magazines and websites in which the analysts help issuers to improve their popularity on the German capital markets.

Analysts
Peter Thilo Hasler

Other Reports on these Companies
Other Reports from Sphene Capital GmbH

ResearchPool Subscriptions

Get the most out of your insights

Get in touch